50 results about "Normal Sinus Rhythm" patented technology

An arrhythmia discrimination device and method involves receiving electrocardiogram signals and non-electrophysiologic signals at subcutaneous locations. Both the electrocardiogram-signals and non-electrophysiologic signals are used to discriminate between normal sinus rhythm and an arrhythmia. An arrhythmia may be detected using electrocardiogram signals, and verified using the non-electrophysiologic signals. A detection window may be initiated in response to receiving the electrocardiogram signal, and used to determine whether the non-electrophysiologic signal is received at a time falling within the detection window. Heart rates may be computed based on both the electrocardiogram signals and non-electrophysiologic signals. The rates may be used to discriminate between normal sinus rhythm and arrhythmia, and used to determining absence of an arrhythmia.

A method and system for discrimination of supraventricular tachycardia and ventricular tachycardia events. Morphological features points are extracted from normal sinus rhythm (NSR) complexes and used to generate a NSR template. A numerical convolution is performed using the NSR template and the feature points for each sensed NSR to give a NSR filter output. Using a plurality of NSR complexes, a median NSR filter output template is determined, where the median NSR filter output template has a median value for each value in the NSR filter output. The median NSR filter output template is then used during a tachycardia event to distinguish tachycardia events as either ventricular tachycardia events or supraventricular tachycardia events.

Apparatus is provided, which includes an electrode device, configured to be coupled to an atrial site of a subject containing parasympathetic nervous tissue, and a control unit. The control unit is configured to, responsively to a detection of an episode of non-sinus atrial tachycardia, restore normal sinus rhythm (NSR) of the subject, by driving the electrode device to apply a parasympathetic stimulation signal to the atrial site, and configuring the parasympathetic stimulation signal to activate the parasympathetic nervous tissue sufficiently to restore the NSR. Other embodiments are also described.

A method of determining a confidence level in a heart rate obtained from an ECG signal of a patent comprises determining a heart rate from a segment of an ECG signal, the segment having a pre-determined length, and determining a first confidence level in the determined heart rate. If the first confidence level exceeds a predetermined value, the heart rate is output. Otherwise, the method further comprises determining a set of features from the segment of the ECG signal; and classifying the segment of the ECG signal, based on one or more features selected from the determined set of features and the heart rate, into one of at least three classes: noise, an abnormal sinus rhythm and a normal sinus rhythm.

An implantable medical device is provided that comprises a housing, sensors configured to be located to proximate a heart, and a sensing module to sense cardiac signals originating from the heart over a channel defined by the sensors. The cardiac signals include intrinsic R-wave events and associated intrinsic confirmation events when the heart exhibits normal sinus rhythm. The device further includes memory to store the cardiac signals sensed over a channel, and a detection module. The detection module identifies an R-wave event within the cardiac signals. The detection module captures, in the memory, a segment of the cardiac signals that precedes the R-wave event as a retrospective segment. The detection module determines whether the retrospective segment includes an intrinsic confirmation event that is associated with and occurs before the R-wave event. The detection module declares an arrhythmia based at least in part on the determination of whether the retrospective segment includes the intrinsic confirmation event is absent from the retrospective segment.

An implantable cardioverter/defibrillator includes a tachycardia detection system that detects one-to-one (1:1) tachycardia, which is a tachycardia with a one-to-one relationship between atrial and ventricular contractions. When the 1:1 tachycardia is detected, the system discriminates ventricular tachycardia (VT) from supraventricular tachycardia (SVT) based on analysis of a cardiac time interval. Examples of the cardiac time interval include an atrioventricular interval (AVI) and a ventriculoatrial interval (VAI). A template time interval is created during a known normal sinus rhythm. The system measures a tachycardia time interval after detecting the 1:1 tachycardia, and indicates a VT detection if the tachycardia time interval differs from the template time interval by at least a predetermined percentage of the template time interval.

A method and system for verifying the integrity of normal sinus rhythm (NSR) templates and updating the NSR template after selected time intervals. At selected time intervals after establishing a NSR template, cardiac complexes are sensed and values for one or more cardiac parameters are measured. The values of the cardiac parameters are compared to predetermined value ranges for NSR cardiac complexes. When the values of the cardiac parameters fall within the predetermined value ranges, values for the differences between the values of the cardiac parameters for the cardiac complexes and the values for the cardiac parameters of the NSR cardiac complexes are calculated. When the values of the differences are greater than one or more threshold values, the NSR template is updated as a function of the sensed cardiac complexes.

Improved methods and devices perform anti-tachycardia pacing (ATP) to convert a ventricular tachycardia (VT) to normal sinus rhythm. In one embodiment of the invention bi-ventricular (BV) ATP is employed. In this embodiment the right ventricle and left ventricle of a patient's heart are independently paced based on signals sensed in each chamber.

A compound of formula (I)

wherein A, R¹, R³, and R²⁴ are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment of arrhythmia, maintaining normal sinus rhythm, I_Kur-associated disorders, and other disorders mediated by ion channel function.

The invention discloses a method for obtaining an artificial neural network weighted value matrix for identifying atrial fibrillation. The method includes the steps of calling an MIT-BIH arrhythmia database, an MIT-BIH normal sinus rhythm database and a long-time atrial fibrillation database as trainning samples, introducing an artificial neural network for learning training, randomly setting the weighted value of each layer of artificial neural network, and inputting training data samples to conduct repeated iteration to correct the weighted value of each layer until the training error is smaller than a designated value. In this way, the weighted value matrix for determining occurrence of atrial fibrillation can be found, the weighted value matrix is added into an original artificial neural network to establish a new artificial neural network, and human electrocardiosignals are processed with the acquired target human electrocardiosignals as data to obtain a target human body characteristic vector X. The prediction operation is carried out according to the target human body characteristic vector X and the new artificial neural network.

The invention relates to a method, a device, electronic equipment and a storage medium for electrocardiogram signal detection and classification. The method comprises the following steps of: extracting a signal waveform from an electrocardiogram signal; acquiring a morphological characteristic and a deep characteristic of the signal waveform, wherein the morphological characteristic comprises anyone of a TR wave amplitude difference characteristic, a PR wave quantity ratio characteristic, an ST wave band characteristic and a P wave variation characteristic, and the deep characteristic comprises a depth characteristic and a hierarchy characteristic; inputting the morphological characteristic and the deep characteristic into a classifier; and acquiring a classification result output by theclassifier so as to obtain the signal type of the electrocardiogram signal, wherein the classification result is a result that the classifier performs classification according to the morphological characteristic and the deep characteristic, and the signal type comprises an atrial fibrillation rhythm, a non-atrial fibrillation abnormal rhythm, a normal sinus rhythm and noise. The method can accurately identify various types of abnormal rhythms, avoids the situation that abnormal rhythms of non-atrial fibrillation types such as tachycardia, bradycardia and arrhythmia are classified into atrial fibrillation types in error, and improves the accuracy of classification of electrocardiogram signals.

The invention discloses a method for obtaining the weight value matrix of the artificial neural network for sudden death risk prediction. The sudden cardiac death database and the MIT-BIH normal sinus rhythm database are constructed into training data samples and cross-validation samples, and each layer of the artificial neural network is randomly set first. Input training data samples to iteratively correct the weight values ​​of each layer until the training error is less than a specified value, find the weight value matrix that can predict the risk of sudden death, and then use the weight value matrix to add the weight value matrix to the original artificial neural network to construct a new model. The artificial neural network, and then use the collected target human ECG signal as data, process the human ECG signal to obtain the target human feature vector X, and perform prediction calculations according to the target human feature vector X and the new artificial neural network, and finally Get the predicted value.

The invention discloses a method for realizing sudden death risk prediction on mini dynamic electrocardiogram monitoring equipment. The method includes: building a sudden cardiac death data base and an MIT-BIH normal sinus rhythm database into a training data sample and a cross validation sample; randomly setting a weight value for each layer of an artificial neural network, inputting the training data sample to repeatedly and iteratively correct the weight value of each layer until training errors are less than a certain specified value, and finding a weight value matrix capable of predicting sudden death risk; utilizing the weight value matrix, and adding the same into an original artificial neural network to build a new artificial neural network; using collected electrocardiosignals of a target human body, processing the electrocardiosignals of the human body, acquiring a target human body feature vector X, and performing prediction operation according to the target human body feature vector X and the new artificial neural network to finally acquire a prediction value.

The invention relates to an improved electrocardiosignal quick clustering analysis method. The method includes steps: windowing electrocardiosignal, and preprocessing data in a window to remove interference; capturing a heart beat fragment from the preprocessed data, and performing time domain or frequency domain processing to obtain a new signal sequence; calculating a similarity coefficient of the sequence, comparing with a threshold to further perform heart beat classification, and extracting an average template of each type; moving the window to a next electrocardiosignal section, and repeating the process until the whole electrocardiosignal clustering is completed; subjecting the average templates obtained in each window to secondary clustering to obtain a final heart beat type and the heart beat quantity and the average template of the corresponding type. The method is suitable for short-term or long-term electrocardiosignals and also suitable for single-lead or multi-lead electrocardiosignals and can be used for electrocardiosignal quick clustering of normal sinus rhythm, single abnormal rhythm or various abnormal rhythms. The method can be popularized in electrocardiosignalactivation analysis and relevant quantitative research.

A heart rate monitor is disclosed. The monitor generates an ST deviation time series by employing a recursive filter that is preferably an exponential average filter whose output is a weighted sum of the then existing ST time series value and current ST deviation values of analyzable beats, seats are detected in segments of data. ST deviation is measured for analyzable beats. The ST deviation time series is updated only if certain criteria are met. A first criterion for updating the time series is that at least half of the beats within a segment must be normal sinus rhythm beats: A second criterion for updating the time series is that (i) the average RR interval of the segment is between¾ and 1.5 times the average RR interval of the previous segment; or (ii) both (a) the number of abnormal beats in the current segment is less than 2, and (b) the number of premature ventricular contractions within the current segment is less than 2.

What is disclosed is a system and method for determining whether a subject is in atrial fibrillation. A video is received of a region of exposed skin of a subject. The video is acquired of a region where a videoplethysmographic (VPG) signal can be registered by at least one imaging channel of a video imaging device. For each batch of image frames, pixels associated with the region of exposed skin are isolated and processed to obtain a time-series signal. A VPG signal is extracted from the time-series signal. The power spectral density (PSD) is computed across all frequencies within the VPG signal. A pulse harmonic strength (PHS) is calculated for this VPG signal. The pulse harmonic strength is compared to a discrimination threshold, defined herein. A determination is made whether the subject in the video is in atrial fibrillation or in normal sinus rhythm.

Disclosed are methods of terminating acute episodes of cardiac arrhythmia, such as atrial fibrillation or ventricular fibrillation, in a mammal, such as a human, by administering to that mammal an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to terminate an acute episode of cardiac arrhythmia and/or restore normal sinus rhythm or heart rate. Also disclosed are methods of maintaining normal sinus rhythm or heart rate in a mammal, such as a human, and preventing a recurrence of an episode of cardiac arrhythmia in a mammal, by administering an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to maintain normal sinus rhythm or heart rate in a mammal that has experienced at least one prior episode of cardiac arrhythmia. Pharmaceutical compositions for use in these methods are also disclosed.

Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.